Significant correlation of TLR4 expression with the clinicopathological features of invasive ductal carcinoma of the breast

Ehsan, Naureen; Murad, Sheeba; Ashiq, Tamour; Mansoor, Muhammad Uzair; Gul, Summer; Khalid, Samra; Younas, Muhammad

doi:10.1007/s13277-013-0645-y

Cited by 25 publications

(17 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the presence of a higher level of TLR-4 protein in breast cancer tissue supports previous studies reporting an overexpression of TLR-4 in various types of cancers, including gastric cancer,42 breast cancer,40,41,43 colon cancer,38,43 and ovarian cancer 44. Higher TLR-4 expression was also shown to be significantly associated with invasive ductal carcinoma, one of the most common types of breast cancer 45. Evidence has demonstrated that TLR-4 activation promotes tumor cell adhesion and metastasis 46,47.…”

Section: Discussionsupporting

confidence: 86%

Toll-like receptor-4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women

Semlali¹,

Jalouli²,

Parine³

et al. 2017

OTT

View full text Add to dashboard Cite

The aim of this study was to investigate the association of the common polymorphisms of Toll-like receptor 4 (TLR-4) with breast cancer development in the Saudi Arabian population. Four TLR-4 polymorphisms (rs2770150, rs10759931, rs10759932, and rs4986790) were studied using 127 breast cancer patients and 117 controls. Relative expression of TLR-4 protein in the breast tumor and the matched normal breast tissues was determined in a large cohort of 70 clinical breast samples in a tissue micro-array format by immunohistochemistry using a specific anti-TLR-4 antibody. Our results demonstrated an increase in TLR-4 expression in estrogen receptor (ER)−, postmenopausal breast cancer patients compared to normal. We also demonstrated that the G allele of single-nucleotide polymorphism rs10759931 was found to be significantly higher in frequency among patients (36.3%) compared to the control group (26.7%), suggesting that this polymorphism is strongly associated with the development of breast cancer in this ethnic population. In addition, the TLR-4 polymorphism rs2770150 was shown to be highly correlated with breast cancer in patients over 48 years of age. The TLR-4 polymorphism rs4986790 was also found to be associated with this malignancy in the ER− patient groups. Our results suggested firstly that the variation in TLR-4 gene expression may influence breast cancer development and secondly a closely linked association between TLR-4 gene polymorphism and ER status. Our study provides support for a better understanding of the implication of TLR-4 polymorphism in breast tumorigenesis and for its eventual use as a cancer biomarker.

show abstract

Section: Discussionsupporting

confidence: 86%

Toll-like receptor-4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women

Semlali¹,

Jalouli²,

Parine³

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…Constitutive expression of some TLR4 genetic variants has also been linked to cancer (28–32). These characteristics are therefore being considered for their prognostic value in cancer treatment (32–34). In these scenarios of established cancer, TLR4 facilitates an environment that is suitable for continued cancer cell proliferation.…”

Section: Tlr4 and Cancermentioning

confidence: 99%

Toll-Like Receptor-4 Modulation for Cancer Immunotherapy

Awasthi

2014

Front. Immunol.

View full text Add to dashboard Cite

“…An immunohistochemical study on clinical carcinomas showed a significant association of high TLR-4 expression with local cancer proliferation and lymph node metastasis 142. A total of 74 breast carcinomas were collected from patients to study the clinical relevance of TLRs in breast cancer.…”

Section: Tlr-4 In Breast Cancermentioning

confidence: 99%

Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers

Wu¹,

Kang²,

Pichika³

2013

OTT

View full text Add to dashboard Cite

Toll-like receptor 4 (TLR-4) is well known for its host innate immunity. Despite the fact that TLR-4 activation confers antitumor responses; emerging evidence suggests that TLR-4 is associated with tumor development and progression. It is now clear that overactivation of TLR-4, through various immune mediators, may cause immune response dysfunction, resulting in tumorigenesis. Different cancers could have different extents of TLR-4 involvement during tumorigenesis or tumor progression. In this review, we focus on infection- and inflammation-related TLR-4 activation in noncancer and cancer cells, as well as on the current evidence about the role of TLR-4 in ten of the most common cancers, viz, head and neck cancer, lung cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, skin cancer, breast cancer, ovarian cancer, cervical cancer, and prostate cancer.

show abstract

Significant correlation of TLR4 expression with the clinicopathological features of invasive ductal carcinoma of the breast

Cited by 25 publications

References 46 publications

Toll-like receptor-4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women

Toll-like receptor-4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women

Toll-Like Receptor-4 Modulation for Cancer Immunotherapy

Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers

Contact Info

Product

Resources

About